JMP Securities Upgrades Halozyme Therapeutics (HALO) to Market Outperform
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $106.12 -1.39%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
JMP Securities upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Market Outperform with a new price target of $9.00.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.20 yesterday.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Barclays Upgrades American Tower (AMT) to Overweight
- Barclays Upgrades Crown Castle (CCI) to Overweight
Create E-mail Alert Related Categories
UpgradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
